RBC Capital downgraded Cidara Therapeutics (CDTX) to Sector Perform from Outperform with a price target of $221.50, up from $145, after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX: